1. Home
  2. NTCT vs MESO Comparison

NTCT vs MESO Comparison

Compare NTCT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTCT
  • MESO
  • Stock Information
  • Founded
  • NTCT 1984
  • MESO 2004
  • Country
  • NTCT United States
  • MESO Australia
  • Employees
  • NTCT N/A
  • MESO N/A
  • Industry
  • NTCT EDP Services
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NTCT Technology
  • MESO Health Care
  • Exchange
  • NTCT Nasdaq
  • MESO Nasdaq
  • Market Cap
  • NTCT 1.7B
  • MESO 1.7B
  • IPO Year
  • NTCT 1999
  • MESO N/A
  • Fundamental
  • Price
  • NTCT $19.84
  • MESO $10.72
  • Analyst Decision
  • NTCT Hold
  • MESO Buy
  • Analyst Count
  • NTCT 1
  • MESO 4
  • Target Price
  • NTCT $25.00
  • MESO $18.00
  • AVG Volume (30 Days)
  • NTCT 544.7K
  • MESO 240.4K
  • Earning Date
  • NTCT 05-08-2025
  • MESO 02-26-2025
  • Dividend Yield
  • NTCT N/A
  • MESO N/A
  • EPS Growth
  • NTCT N/A
  • MESO N/A
  • EPS
  • NTCT N/A
  • MESO N/A
  • Revenue
  • NTCT $821,135,000.00
  • MESO $5,670,000.00
  • Revenue This Year
  • NTCT $0.22
  • MESO $228.57
  • Revenue Next Year
  • NTCT $2.04
  • MESO $356.77
  • P/E Ratio
  • NTCT N/A
  • MESO N/A
  • Revenue Growth
  • NTCT N/A
  • MESO N/A
  • 52 Week Low
  • NTCT $17.10
  • MESO $4.60
  • 52 Week High
  • NTCT $27.89
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • NTCT 39.59
  • MESO 38.38
  • Support Level
  • NTCT $19.73
  • MESO $10.26
  • Resistance Level
  • NTCT $20.69
  • MESO $11.33
  • Average True Range (ATR)
  • NTCT 0.83
  • MESO 0.75
  • MACD
  • NTCT 0.02
  • MESO 0.06
  • Stochastic Oscillator
  • NTCT 49.28
  • MESO 37.37

About NTCT NetScout Systems Inc.

NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: